{"id":4151,"date":"2025-03-31T18:11:59","date_gmt":"2025-03-31T18:11:59","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/lomustine-txt\/"},"modified":"2025-03-31T18:11:59","modified_gmt":"2025-03-31T18:11:59","slug":"lomustine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/lomustine-txt\/","title":{"rendered":"Lomustine.txt"},"content":{"rendered":"

Lomustine <\/h1>\n

CLINICAL USE <\/H3>
\nTreatment of Hodgkin\u2019s disease and certain solid tumours

DOSE IN NORMAL RENAL FUNCTION <\/H3>120\u2013130 mg\/m2 every 6\u20138 weeks if used alone; lower dose is used in combination treatment and compromised bone marrow function

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :233.7<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 50 (as metabolites)<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :16\u201348 (metabolites)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>45\u201360 75% of dose30\u201345 50\u201370% of dose<30 Not recommended.

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Avoid<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Avoid.
  • HDF\/high flux &nbsp :Unknown dialysability. Avoid. See \u2018Other Information\u2019
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Avoid. See \u2018Other Information\u2019

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • None known

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Bone marrow toxicity is delayed Relatively rapid and complete oral absorption, followed by first pass metabolism. Part of lomustine metabolism is mediated through hepatic microsomal enzymes. Metabolites predominantly excreted by kidneys; 10% excreted as CO2 and < 5% in faeces
    \n","protected":false},"excerpt":{"rendered":"

    Lomustine CLINICAL USE Treatment of Hodgkin\u2019s disease and certain solid<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4151","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4151"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4151\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}